Safety profiles of the angiotensin converting enzyme inhibitors captopril and enalapril.
The safety profiles of the angiotensin converting enzyme inhibitors, captopril and enalapril, are the focus of this review. Adverse effects are reviewed as those associated with sulfhydryl compounds and as those considered class-specific adverse effects of angiotensin converting enzyme inhibitors. Specifically discussed are the incidences of the adverse effects of rash, taste disturbance, neutropenia, and proteinuria, which are characteristic of compounds containing sulfhydryl moieties, such as captopril. It is concluded from the review of these safety data that enalapril is well tolerated, has few class-specific adverse effects, and may offer a potential advantage over captopril by having fewer sulfhydryl-related adverse effects.
D000806:Angiotensin-Converting Enzyme Inhibitors; D001794:Blood Pressure / Q000187:drug effects; D002216:Captopril / Q000008:administration & dosage / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D004244:Dizziness / Q000139:chemically induced; D004305:Dose-Response Relationship, Drug; D004656:Enalapril / Q000009:adverse effects* / Q000378:metabolism; D006207:Half-Life; D006261:Headache / Q000139:chemically induced; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D007674:Kidney Diseases / Q000150:complications; D009503:Neutropenia / Q000139:chemically induced; D009842:Oligopeptides / Q000009:adverse effects*; D012871:Skin Diseases / Q000139:chemically induced; D013438:Sulfhydryl Compounds / Q000009:adverse effects; D013651:Taste Disorders / Q000139:chemically induced; D013722:Teprotide
D000806:Angiotensin-Converting Enzyme Inhibitors; D009842:Oligopeptides; D013438:Sulfhydryl Compounds; D004656:Enalapril; D002216:Captopril; D013722:Teprotide